Claims
- 1. A method for modulating an ischemic event in a subject, said method comprising:
providing the subject with a gene-regulatory peptide or functional analogue thereof.
- 2. The method according to claim 1 wherein said gene-regulatory peptide or functional analogue thereof down-regulates translocation, activity, or translocation and activity of a gene transcription factor.
- 3. The method according to claim 2 wherein said gene transcription factor comprises an NF-kappaB/Rel protein.
- 4. The method according to claim 3 wherein translocation, activity, or translocation and activity of said NF-kappaB/Rel protein is inhibited.
- 5. The method according to claim 1 wherein said gene-regulatory peptide or functional analogue thereof has NFkappaB down-regulating activity in LPS stimulated RAW264.7 cells.
- 6. The method according to claim 2 wherein said gene-regulatory peptide or functional analogue thereof has NFkappaB down-regulating activity in LPS stimulated RAW264.7 cells.
- 7. The method according to claim 3 wherein said gene-regulatory peptide or functional analogue thereof has NFkappaB down-regulating activity in LPS stimulated RAW264.7 cells.
- 8. The method according to claim 4 wherein said gene-regulatory peptide or functional analogue thereof has NFkappaB down-regulating activity in LPS stimulated RAW264.7 cells.
- 9. The method according to claim 1 wherein the subject is at risk of experiencing reperfusion injury after said ischemic event.
- 10. The method according to claim 2 wherein the subject is at risk of experiencing reperfusion injury after said ischemic event.
- 11. The method according to claim 3 wherein the subject is at risk of experiencing reperfusion injury after said ischemic event.
- 12. The method according to claim 4 wherein the subject is at risk of experiencing reperfusion injury after said ischemic event.
- 13. The method according to claim 5 wherein the subject is at risk of experiencing reperfusion injury after said ischemic event.
- 14. The method according to claim 6 wherein the subject is at risk of experiencing reperfusion injury after said ischemic event.
- 15. The method according to claim 7 wherein the subject is at risk of experiencing reperfusion injury after said ischemic event.
- 16. The method according to claim 8 wherein the subject is at risk of experiencing reperfusion injury after said ischemic event.
- 17. The method according to any one of claims 1 through 16 wherein said gene-regulatory peptide or functional analogue thereof has NFkappaB down-regulating activity in LPS unstimulated RAW264.7 cells.
- 18. The method according to claim 1 further comprising:
also providing the subject with a therapeutic amount of a thrombolytic agent.
- 19. The method according to claim 8 wherein the thrombolytic agent has tissue plasminogen activity.
- 20. A method for treating an ischemic event in a subject, said method comprising:
inhibiting, in the subject, a gene transcription factor comprising NF-kappaB/Rel protein by providing the subject with a gene-regulatory peptide so as to down-regulate translocation, activity, or translocation and activity of the gene transcription factor, thus treating the subject's ischemic event.
CROSS-REFERENCE TO RELATED APPLICATION
[0001] This application is a continuation-in-part of U.S. patent application Ser. No. 10/028,075, filed Dec. 21, 2001, pending, the content of the entirety of which is incorporated by this reference.
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
10028075 |
Dec 2001 |
US |
Child |
10409642 |
Apr 2003 |
US |